Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
AVIR on Nasdaq
Shares outstanding
78,411,033
Price per share
$3.57
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
53,140,827
Total reported value
$154,099,214
% of total 13F portfolios
0%
Share change
+445,216
Value change
+$874,829
Number of holders
111
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +70% $29,470,003 +$10,937,987 9,095,680 +59% FMR LLC 28 Nov 2025
Sommadossi Jean-Pierre 10% $26,540,594 8,876,453 Jean-Pierre Sommadossi 31 Mar 2025
BML Investment Partners, L.P. 8.5% $21,576,773 7,216,312 Leonard Braden Michael 13 Dec 2024
BlackRock, Inc. 7.1% $18,186,226 6,082,350 BlackRock, Inc. 31 Mar 2025
Radoff Bradley Louis 4% +10% $10,106,499 +$822,250 3,380,100 +8.9% Radoff Bradley Louis 16 Apr 2025
EcoR1 Capital, LLC 4% $9,991,542 3,341,653 EcoR1 Capital, LLC 31 Dec 2024

As of 30 Sep 2025, 111 institutional investors reported holding 53,140,827 shares of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR). This represents 68% of the company’s total 78,411,033 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 8,459,220 -2.4% 0% $24,531,739
BML Capital Management, LLC 9.5% 7,473,963 -1.8% 20% $21,674,493
FMR LLC 7.4% 5,822,773 +1.8% 0% $16,886,041
TANG CAPITAL MANAGEMENT LLC 6.2% 4,826,200 -1.3% 0.54% $13,995,980
VANGUARD GROUP INC 6% 4,709,275 -3.6% 0% $13,656,897
Bain Capital Life Sciences Investors, LLC 3.2% 2,485,638 0% 0.48% $7,208,350
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,899,737 -1.3% 0% $5,510,507
STATE STREET CORP 2.3% 1,783,976 +0.43% 0% $5,173,530
DIMENSIONAL FUND ADVISORS LP 2% 1,540,716 +9.2% 0% $4,468,201
RENAISSANCE TECHNOLOGIES LLC 1.6% 1,227,900 -0.5% 0% $3,560,910
ACADIAN ASSET MANAGEMENT LLC 1.2% 969,773 +5.7% 0% $2,810,000
TWO SIGMA ADVISERS, LP 1% 796,200 +14% 0% $2,308,980
NORTHERN TRUST CORP 0.81% 638,388 -5.5% 0% $1,851,325
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.8% 624,984 -1.6% 0% $1,812,454
JPMORGAN CHASE & CO 0.79% 616,851 -5.5% 0% $1,788,869
CM Management, LLC 0.64% 500,000 0% 1.2% $1,450,000
Newtyn Management, LLC 0.63% 492,284 -15% 0.17% $1,427,624
MILLENNIUM MANAGEMENT LLC 0.62% 487,223 +179% 0% $1,412,947
TWO SIGMA INVESTMENTS, LP 0.6% 471,293 +29% 0% $1,366,750
Peapod Lane Capital LLC 0.58% 457,216 +1% 1.2% $1,325,921
MORGAN STANLEY 0.57% 450,564 -17% 0% $1,306,636
JACOBS LEVY EQUITY MANAGEMENT, INC 0.51% 398,423 +37% 0% $1,155,427
D. E. Shaw & Co., Inc. 0.47% 364,768 +86% 0% $1,057,827
BANQUE PICTET & CIE SA 0.44% 345,077 0% 0.01% $1,000,723
GOLDMAN SACHS GROUP INC 0.43% 340,140 +14% 0% $986,406

Institutional Holders of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 212,242 $757,355 -$34,381 $3.57 3
2025 Q3 53,140,827 $154,099,214 +$874,829 $2.90 111
2025 Q2 52,688,325 $189,687,193 -$496,597 $3.60 105
2025 Q1 52,943,893 $158,295,914 -$11,408,008 $2.99 102
2024 Q4 56,328,624 $188,653,231 -$6,771,103 $3.35 103
2024 Q3 57,907,511 $193,998,808 +$4,533,747 $3.35 105
2024 Q2 56,687,549 $187,637,541 +$7,269,182 $3.31 101
2024 Q1 54,294,109 $219,348,640 -$1,665,575 $4.04 110
2023 Q4 33,286 $101,522 $3.05 1
2023 Q3 56,804,345 $170,414,101 -$1,905,485 $3.00 115
2023 Q2 57,004,341 $213,151,865 +$726,156 $3.74 130
2023 Q1 56,770,020 $190,134,139 -$5,742,306 $3.35 127
2022 Q4 57,809,629 $278,063,423 -$5,112,897 $4.81 127
2022 Q3 56,926,773 $323,916,136 -$1,872,038 $5.69 111
2022 Q2 57,172,355 $405,461,574 +$19,291,179 $7.10 119
2022 Q1 52,444,379 $378,472,373 -$6,725,543 $7.22 116
2021 Q4 52,743,032 $471,490,823 -$415,604,329 $8.94 129
2021 Q3 56,823,502 $1,991,977,650 -$21,909,639 $35.06 138
2021 Q2 58,896,842 $1,265,509,812 +$154,398,461 $21.48 100
2021 Q1 49,438,743 $3,041,039,173 +$30,510,281 $61.75 80
2020 Q4 49,910,976 $2,070,766,859 +$1,819,869,733 $41.78 69